CMAJ • August 28, 2007; 177 (5). First published August 1, 2007; doi:10.1503/cmaj.070948
© 2007 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Résumé
Right arrow Online Appendix
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rambout, L.
Right arrow Articles by Fergusson, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rambout, L., BScPhm
Right arrow Articles by Fergusson, D., PhD
Related Collections
Right arrow Drugs: immunological products and vaccines
Right arrow Sexually transmitted infections
Right arrow Vaccination
Right arrow Français
Right arrowRelated Articles

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials

Lisa Rambout, BScPhm, Laura Hopkins, MD MSc, Brian Hutton, MSc and Dean Fergusson, PhD

From the Department of Pharmacy (Rambout), the Ottawa Health Research Institute (Hutton, Fergusson) and the Clinical Epidemiology Program (Fergusson), The Ottawa Hospital; and the Division of Gynecologic Oncology (Hopkins), Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Ont.


Figure 119
View larger version (23K):
[in this window]
[in a new window]

  		Figure 1: Selection of studies for meta-analysis.

 

View this table:
[in this window]
[in a new window]

  		Table 1.

 

View this table:
[in this window]
[in a new window]

  		Table 2.

 

View this table:
[in this window]
[in a new window]

  		Table 3.

 

Figure 219
View larger version (32K):
[in this window]
[in a new window]

  		Figure 2: Per-protocol meta-analysis of clinically important outcomes in selected studies of prophylactic vaccination against human papillomavirus (HPV)-related infection and disease. (Per-protocol analyses included study participants who were seronegative and DNA negative for relevent HPV types at enrolment and who received all 3 doses of vaccine.) CIN = cervical intraepithelial neoplasia.

 

Figure 319
View larger version (39K):
[in this window]
[in a new window]

  		Figure 3: Modified intention-to-treat meta-analysis of clinically important outcomes in selected studies of prophylactic vaccination against human papillomavirus (HPV)-related infection and disease. (Modified intention-to-treat analyses included study participants who received at least 1 dose of vaccine and who either were negative for relevant HPV types at enrolment [Harper, Villa, PATRICIA] or were randomly assigned to study group irrespective of their baseline HPV status [Mao, FUTURE I, FUTURE II].) CIN = cervical intraepithelial neoplasia.

 

Figure 419
View larger version (22K):
[in this window]
[in a new window]

  		Figure 4: Meta-analysis of serious adverse events and death in selected studies of prophylactic vaccination against HPV-related infection and disease.